Peptides 101: What They Are, How They Work, and What to Know Before Starting

The word “peptide” gets used a lot right now. It shows up on supplement labels, in podcast ads, on social media, and in conversations between friends comparing notes on what’s working. The category has become genuinely popular — and like anything popular in health, the louder the conversation gets, the more inaccurate it tends to become.

This article is a clear introduction to peptide therapy: what these molecules actually are, how they work in the body, why your body is already making them, why the source of any peptide you take matters more than most patients realize, and what good clinical care looks like in this space. We’ve tried to write this the way a careful physician would explain it across the desk — without the marketing voice, without the overconfidence, and without the pretense that all peptides are the same thing.

The simplest possible explanation: what a peptide actually is

Imagine your body is made of millions of tiny machines. The parts of those machines are called amino acids. There are twenty kinds of amino acids in your body, and they snap together like beads on a string to build everything from your muscles to your hormones to your immune system.

When you connect a few amino acids together — usually somewhere between two and fifty — you get a peptide. When you connect a lot more, you get a protein. So a peptide is just a small protein. That’s the whole definition.

Here is the important part: your body is making peptides every second of every day. You don’t have to ingest them or inject them — your body produces them naturally as part of normal biology. Insulin, which controls your blood sugar, is a peptide. Oxytocin, the hormone released when you hug someone you love, is a peptide. Glucagon-like peptide-1 (GLP-1), the hormone your gut releases after a meal to tell your brain you’re full, is a peptide. Growth hormone-releasing hormone, which signals your pituitary to release growth hormone, is a peptide.

This matters because it changes how you should think about peptide therapy. The peptides used in medicine are not foreign chemicals being introduced into a clean system. In most cases, they are either identical to molecules your body already produces, or close variations of them, designed to last longer or bind more strongly to a specific receptor. Therapeutic peptides work because your body already speaks their language. The receptors are already there. The pathways already exist. The peptide just delivers the signal.

That’s the basic biology. A peptide is a small chain of amino acids. Your body makes them constantly. Therapeutic peptides borrow that same signaling system to address specific clinical concerns.

“Peptides” is not one thing — it’s a whole category of medicines

One of the most common misconceptions about peptide therapy is that “peptides” refers to a single substance, like “aspirin” or “ibuprofen.” It does not. Peptides are a category of molecules, the same way “antibiotics” or “blood pressure medications” are categories.

Within the antibiotics category, you have penicillin, amoxicillin, azithromycin, doxycycline, and dozens of others. Each one targets specific bacteria, has specific uses, and has specific side effects. A doctor doesn’t prescribe “an antibiotic” — they prescribe a particular antibiotic for a particular infection.

Peptide therapy works the same way. Within the peptide category, there are many specific peptides, each with its own structure, mechanism, and clinical purpose. A few examples to make this concrete:

• Semaglutide is a peptide that mimics GLP-1 to regulate blood sugar and appetite. It’s the active ingredient in Ozempic and Wegovy. It has nothing to do with tendon healing.
• BPC-157 is a peptide derived from a protein in human gastric juice. It appears to support tissue repair, particularly in tendons, ligaments, and the gut lining. It has nothing to do with metabolism.
• Sermorelin is a peptide that signals the pituitary gland to release growth hormone in its natural pulsatile pattern. It has nothing to do with immune function.
• Thymosin alpha-1 is a peptide produced by the thymus gland that supports T-cell function and immune regulation. It has nothing to do with body composition.
• PT-141 (bremelanotide) is a peptide that acts on melanocortin receptors in the central nervous system to influence sexual desire. It’s FDA-approved for that specific purpose. It has nothing to do with sleep or recovery.

Each of these is a peptide. None of them is interchangeable with another. They target different receptors, work through different pathways, and serve different clinical purposes. When someone asks “do peptides work?”, the only honest answer is “which peptide, for what?”

This is also why one-size-fits-all peptide protocols don’t make clinical sense. A patient with metabolic concerns doesn’t need the same peptide as a patient with a chronic tendon injury. A patient seeking sleep support shouldn’t be given the same protocol as a patient working on lean mass retention. The peptide has to match the patient and the goal — which requires actually knowing the patient and the goal.

How peptides work in the body

Most cells in your body have receptors on their surface — molecular “locks” that respond when the right “key” arrives. Hormones, neurotransmitters, and many medications work this way. The right molecule binds to the right receptor and triggers a specific response inside the cell.

Peptides are highly specific keys. Because they’re built from the same amino acids your body uses for its own signaling molecules, peptides can be designed to fit very precisely into particular receptors and trigger particular pathways. This is what makes them clinically useful: instead of broad pharmacological effects that hit many systems at once, a well-designed peptide can produce a targeted signal in a targeted tissue.

An analogy: a small-molecule drug is often like shouting in a crowded room — many people hear the message, including some you didn’t want to talk to. A peptide is more like a private conversation — the message goes to the specific person it was meant for. That precision is the appeal of the category and is why peptide research has accelerated rapidly over the past decade. It’s also why peptides require careful clinical thinking — the precision means you need to choose the right peptide for the right physiological problem.

Where your peptides come from matters more than most people realize

This is the section of any peptide article that gets the least attention and deserves the most, because the source of a peptide can determine its safety, its purity, and whether it’s even legally permitted to be administered to a person.

Therapeutic peptides in the United States generally fall into three regulatory categories, and the differences are not subtle.

FDA-approved peptides are pharmaceutical products that have completed the full clinical trial and regulatory approval process for specific indications. Semaglutide, tirzepatide, and PT-141 are examples. These are manufactured by pharmaceutical companies under strict quality controls, dispensed by licensed pharmacies, and have published clinical trial data demonstrating safety and efficacy for their approved uses.

Compounded peptides are produced by licensed compounding pharmacies. There are two kinds of compounding pharmacies under U.S. law: 503A pharmacies, which compound medications for individual patients based on a specific prescription, and 503B outsourcing facilities, which can compound at larger scale under tighter manufacturing standards similar to pharmaceutical manufacturers. Many regenerative and growth hormone-supporting peptides — BPC-157, TB-500, sermorelin, ipamorelin — are obtained through compounding pharmacies. When prescribed by a licensed physician and sourced from a vetted, accredited compounding pharmacy, compounded peptides can be a legitimate part of clinical care.

Research peptides are sold by chemical supply companies labeled “for research use only — not for human consumption.” These are not regulated for human use. There is no requirement for sterility testing, no quality assurance for what’s actually in the vial, no oversight on dosing, and no recourse if something goes wrong. The FDA does not consider these legal for administration to humans, and physicians do not prescribe them.

The distinction matters because the public conversation about peptides often blurs these categories. Online forums and social media discussions of peptide use frequently reference research peptides being self-administered without medical supervision. Some online clinics have been documented sourcing peptides from suppliers whose chain of custody is unclear. The result is that two patients can both believe they are taking “BPC-157” and have very different experiences depending entirely on what was actually in the vial they received.

Quality at the source affects everything downstream. A peptide compounded by an accredited 503A pharmacy that has been through state inspection and follows USP standards is fundamentally different from a vial purchased online from an unverified source. The molecule may have the same name. What’s actually in the vial may not be the same substance. Sourcing is not a detail. It is the foundation of whether peptide therapy is medicine or guesswork.

For patients evaluating peptide therapy, this means asking direct questions before starting any protocol. Where is the peptide coming from? Is the pharmacy licensed and inspected? What is the chain of custody from manufacturer to compounding pharmacy to patient? What quality testing is performed? A clinic that can answer these questions clearly is operating in the appropriate part of the regulatory landscape. A clinic that cannot — or that gets defensive when asked — is signaling something important about how it operates.

Patient outcomes depend on much more than the peptide itself

One of the most common misconceptions about peptide therapy — and about prescription medicine in general — is that the molecule does the work, and the rest is paperwork. In reality, the peptide is one variable among many. The clinical structure around it determines whether the molecule produces the outcome the patient was hoping for.

Consider what actually has to be right for a peptide protocol to succeed:

The right peptide for the right problem. This requires accurate diagnosis, which requires a real clinical evaluation. A patient who comes in saying “I’m tired all the time” might benefit from a peptide protocol — or might benefit much more from sleep medicine, hormone replacement, treatment of an underlying condition, or simple lifestyle interventions. The peptide is only the right tool if the underlying problem is the kind of problem peptides are designed to address.

The right dose for the specific patient. Peptide dosing is not standardized like an antibiotic. Effective doses vary by body composition, age, sex, baseline biomarkers, treatment goals, and individual response. Templated dosing — the same protocol prescribed to every patient — produces inconsistent outcomes and unnecessary side effects.

Baseline labs and ongoing monitoring. Many peptide protocols affect biomarkers that should be tracked — IGF-1, fasting glucose and insulin, lipids, hormones, inflammatory markers. Without baseline measurement, there is no way to assess whether the protocol is working, whether it should be adjusted, or whether it should be stopped. Without follow-up labs, the same is true. Patients who are dispensed a peptide and never measured again are not receiving clinical care; they are receiving a transaction.

Cycle structure and stopping criteria. Peptides are not generally taken indefinitely. Most protocols involve cycles — periods of treatment followed by periods of rest — to maintain receptor sensitivity and avoid undesirable adaptations. The design of the cycle matters as much as the peptide itself, and it requires clinical judgment.

Adjustment over time. The first protocol a patient starts is rarely the protocol they remain on long-term. Doses are titrated based on response. Peptides are added or removed based on lab trends and patient experience. Side effects are managed. Goals evolve. A clinic that hands you a vial and a schedule and never adjusts is not practicing medicine; it is filling a prescription.

This is what is meant when serious peptide clinicians talk about “hands-on care.” The phrase isn’t marketing. It’s a reflection of what the work actually requires. A patient who walks into a peptide consultation, fills out a form, receives a vial in the mail, and never speaks with a clinician again is participating in something that resembles peptide therapy without including most of what makes peptide therapy effective.

The patients who do best with peptide protocols tend to be the ones whose clinicians took the time to do the work — the consultation, the labs, the protocol design, the follow-up at thirty and sixty and ninety days, the adjustments based on what the data showed. None of this is glamorous. All of it is what separates good outcomes from disappointing ones.

What can peptide therapy actually do?

The honest answer to this question is: it depends entirely on which peptide and which clinical goal. Some peptides have decades of human clinical evidence and are FDA-approved for specific uses. Others have substantial preclinical data and accumulating practitioner experience but limited human trials. Others still are genuinely investigational, with mechanisms that look promising but outcomes that haven’t been adequately tested in people.

Broadly, peptides used in clinical practice fall into several functional areas:

Metabolic health. The GLP-1 class — semaglutide, tirzepatide — has the strongest evidence base in modern peptide medicine, with large clinical trials demonstrating effects on blood sugar, body weight, and cardiovascular outcomes. This is the area of peptide therapy where the public conversation is most accurate to the science.

Tissue repair and recovery. Peptides like BPC-157, TB-500, and GHK-Cu are used in clinical practice for tendon and ligament healing, post-surgical recovery, and chronic soft-tissue injuries. The preclinical evidence is robust; the human evidence is more limited and is still developing.

Growth hormone support. Peptides such as sermorelin, ipamorelin, and CJC-1295 stimulate the body’s own pulsatile release of growth hormone. They are used clinically for adults with documented declines in growth hormone secretion and for support of recovery and lean mass in appropriate patients.

Sleep, cognition, and neuroprotection. Peptides including DSIP, Selank, and Semax target pathways involved in sleep architecture, stress response, and neurotrophic function. The strongest clinical literature in this area comes from Eastern European research, and a careful clinician will be transparent about that.

Immune modulation and gut health. Thymosin alpha-1 has decades of international clinical use for immune support. Oral BPC-157 protocols are used for gut barrier and inflammation considerations.

Sexual health. PT-141 (bremelanotide) is FDA-approved for sexual desire and acts on a central nervous system pathway distinct from hormones or vascular medications.

Longevity and healthspan. This is the area of peptide therapy where overclaiming is most common and where appropriate clinical caution is most important. Animal data is frequently exciting; human outcomes data is frequently preliminary. Patients in this space deserve clinicians who are honest about the difference.

Across all of these areas, the same principle applies: the peptide alone doesn’t determine the outcome. The clinical structure around it does.

What about the risks?

Every medication carries risk, and peptides are no exception. The honest accounting includes a few categories worth understanding before any protocol:

Side effects vary by peptide. GLP-1 medications commonly cause nausea and gastrointestinal symptoms, particularly during titration. Growth hormone-supporting peptides can affect insulin sensitivity. Some peptides have specific contraindications in patients with active cancer or certain hormone-sensitive conditions. The relevant side effect profile depends on the specific peptide and the specific patient.

Sourcing risk is the largest avoidable risk. A peptide from an unverified source can be contaminated, mislabeled, or dosed incorrectly. This is the risk that has nothing to do with peptides themselves and everything to do with where the medicine came from.

The evidence base is uneven across the category. Some peptides have decades of human clinical trials. Others have animal studies and clinical experience but limited controlled human data. A responsible clinician should be able to tell you which category your specific protocol falls into and what that means for your decision.

Drug interactions and medical context matter. Peptides can interact with prescriptions, supplements, and other therapies. They can be inappropriate for patients with certain medical conditions. A consultation that doesn’t review your full medical picture isn’t doing the work the medicine requires.

How to think about whether peptide therapy is right for you

Peptide therapy is a clinical decision, not a consumer purchase. The question of whether it’s right for any individual patient depends on the goal, the medical history, what’s already been tried, and what the realistic alternatives are.

The patients who tend to benefit most from peptide protocols share a few traits. They have a specific clinical concern that peptides are well-suited to address — a metabolic problem, a recovery issue, a hormonal decline, a measurable biomarker imbalance. They’re willing to do the work that good clinical care requires — labs, follow-up appointments, protocol adjustments over time. They want to understand what they’re taking and why, rather than just trusting that someone else has figured it out.

The patients who tend to be disappointed by peptide therapy are those who expected a fast and global fix, weren’t given a clear protocol with appropriate monitoring, or received their peptides through channels that didn’t include real clinical evaluation in the first place. In most of those cases, the disappointing outcome wasn’t the peptide’s fault. It was the absence of the structure around it.

The most useful step for anyone considering peptide therapy is a real clinical consultation with a clinician who specializes in this work — someone who will take the time to understand the goal, review the medical context, order the appropriate baseline labs, design a protocol that fits the individual rather than the template, and follow up to see whether the protocol is doing what it was meant to do.

That’s what good peptide medicine looks like. It’s slower than the marketing suggests, more individualized than the templated protocols allow, and far more dependent on clinical structure than on any single molecule. But for the right patient, with the right care, it can be a meaningful part of how modern medicine addresses problems that older approaches don’t reach.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas, located adjacent to the Texas Medical Center. We were built around a single category of medicine — peptide therapy and the related areas of metabolic health, hormone optimization, recovery, sleep, immune support, sexual health, and longevity — rather than offering peptides as one item on a broader menu. Our approach centers on physician-led consultations, baseline lab work, individualized protocols, and ongoing monitoring at thirty, sixty, and ninety days. We source from vetted 503A and 503B compounding pharmacies and prescribe FDA-approved peptides where indicated. For Houston patients exploring peptide therapy, our peptide library, programs, and clinical standards describe how we work in detail.

This article is part of an ongoing educational library on peptide therapy. For deeper reading on specific peptides, regulatory categories, or clinical applications, see the full peptide library at The Tide.